AU757689B2 - Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use - Google Patents
Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use Download PDFInfo
- Publication number
- AU757689B2 AU757689B2 AU61926/99A AU6192699A AU757689B2 AU 757689 B2 AU757689 B2 AU 757689B2 AU 61926/99 A AU61926/99 A AU 61926/99A AU 6192699 A AU6192699 A AU 6192699A AU 757689 B2 AU757689 B2 AU 757689B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- alkylene
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19845406 | 1998-10-02 | ||
| DE19845406A DE19845406C2 (de) | 1998-10-02 | 1998-10-02 | Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| PCT/EP1999/006933 WO2000020393A1 (de) | 1998-10-02 | 1999-09-18 | Substituierte 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6192699A AU6192699A (en) | 2000-04-26 |
| AU757689B2 true AU757689B2 (en) | 2003-03-06 |
Family
ID=7883187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU61926/99A Ceased AU757689B2 (en) | 1998-10-02 | 1999-09-18 | Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6596728B1 (enExample) |
| EP (1) | EP1117642B1 (enExample) |
| JP (1) | JP4544746B2 (enExample) |
| KR (1) | KR100609255B1 (enExample) |
| CN (1) | CN1173951C (enExample) |
| AR (1) | AR021845A1 (enExample) |
| AT (1) | ATE267809T1 (enExample) |
| AU (1) | AU757689B2 (enExample) |
| BR (1) | BR9915027B1 (enExample) |
| CA (1) | CA2345985C (enExample) |
| CZ (1) | CZ299569B6 (enExample) |
| DE (2) | DE19845406C2 (enExample) |
| DK (1) | DK1117642T3 (enExample) |
| ES (1) | ES2219066T3 (enExample) |
| HU (1) | HU226688B1 (enExample) |
| ID (1) | ID29249A (enExample) |
| PL (1) | PL205034B1 (enExample) |
| PT (1) | PT1117642E (enExample) |
| RU (1) | RU2224748C2 (enExample) |
| TR (1) | TR200100896T2 (enExample) |
| WO (1) | WO2000020393A1 (enExample) |
| ZA (1) | ZA200102587B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431995A1 (en) | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| DE10064402A1 (de) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Gmbh | Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| JP2005505538A (ja) * | 2001-08-22 | 2005-02-24 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アリール置換プロパノールアミン誘導体と他の活性成分との組み合わせ物およびその使用 |
| US7161008B2 (en) * | 2002-05-03 | 2007-01-09 | Sanofi - Aventis Deutschland GmbH | Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them |
| DE10219987A1 (de) * | 2002-05-03 | 2004-04-08 | Aventis Pharma Deutschland Gmbh | Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| US7816353B2 (en) * | 2003-10-24 | 2010-10-19 | Exelixis, Inc. | P70S6 kinase modulators and method of use |
| EP4137137A1 (en) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| EA038594B1 (ru) | 2011-10-28 | 2021-09-21 | Шайр Хьюман Дженетик Терапис, Инк. | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| KR20160002773A (ko) | 2013-03-15 | 2016-01-08 | 루메나 파마수티컬즈, 인코포레이티드 | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
| AU2014229050A1 (en) | 2013-03-15 | 2015-10-22 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease |
| JP6361168B2 (ja) * | 2013-06-17 | 2018-07-25 | Jsr株式会社 | 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物 |
| EP4424363B1 (en) | 2019-02-12 | 2026-04-29 | Mirum Pharmaceuticals, Inc. | Methods for increasing growth in pediatric subjects having cholestatic liver disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0000816A1 (en) * | 1977-08-06 | 1979-02-21 | Beecham Group Plc | Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| SU1194273A3 (ru) * | 1981-02-09 | 1985-11-23 | Пфайзер Инк (Фирма) | Способ получени пирбутерола или его аналогов |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| ES2098570T3 (es) * | 1992-02-22 | 1997-05-01 | Hoechst Ag | Amidas de un acido 4-amino-2-ureido-pirimidina-5-carboxilico, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion. |
| DE19845402B4 (de) * | 1998-10-02 | 2005-04-07 | Aventis Pharma Deutschland Gmbh | Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| ATE268758T1 (de) | 1997-04-04 | 2004-06-15 | Aventis Pharma Gmbh | Hypolipidämische propanolaminderivate |
| DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
-
1998
- 1998-10-02 DE DE19845406A patent/DE19845406C2/de not_active Expired - Fee Related
-
1999
- 1999-09-18 PT PT99948791T patent/PT1117642E/pt unknown
- 1999-09-18 TR TR2001/00896T patent/TR200100896T2/xx unknown
- 1999-09-18 CN CNB99811636XA patent/CN1173951C/zh not_active Expired - Fee Related
- 1999-09-18 ES ES99948791T patent/ES2219066T3/es not_active Expired - Lifetime
- 1999-09-18 WO PCT/EP1999/006933 patent/WO2000020393A1/de not_active Ceased
- 1999-09-18 DK DK99948791T patent/DK1117642T3/da active
- 1999-09-18 CZ CZ20011152A patent/CZ299569B6/cs not_active IP Right Cessation
- 1999-09-18 BR BRPI9915027-1A patent/BR9915027B1/pt not_active IP Right Cessation
- 1999-09-18 KR KR1020017004096A patent/KR100609255B1/ko not_active Expired - Fee Related
- 1999-09-18 JP JP2000574510A patent/JP4544746B2/ja not_active Expired - Fee Related
- 1999-09-18 AU AU61926/99A patent/AU757689B2/en not_active Ceased
- 1999-09-18 PL PL347096A patent/PL205034B1/pl unknown
- 1999-09-18 AT AT99948791T patent/ATE267809T1/de active
- 1999-09-18 HU HU0103533A patent/HU226688B1/hu not_active IP Right Cessation
- 1999-09-18 EP EP99948791A patent/EP1117642B1/de not_active Expired - Lifetime
- 1999-09-18 ID IDW20010736A patent/ID29249A/id unknown
- 1999-09-18 CA CA2345985A patent/CA2345985C/en not_active Expired - Fee Related
- 1999-09-18 RU RU2001111841/04A patent/RU2224748C2/ru not_active IP Right Cessation
- 1999-09-18 DE DE59909606T patent/DE59909606D1/de not_active Expired - Lifetime
- 1999-09-30 AR ARP990104960A patent/AR021845A1/es active IP Right Grant
- 1999-10-01 US US09/410,083 patent/US6596728B1/en not_active Expired - Lifetime
-
2001
- 2001-03-29 ZA ZA200102587A patent/ZA200102587B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0772590B1 (en) | Thrombin inhibitors | |
| US5719296A (en) | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins | |
| AU726585B2 (en) | Biarylalkanoic acids as cell adhesion inhibitors | |
| JP4130519B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| AU2007342223B2 (en) | Compounds and compositions as channel activating protease inhibitors | |
| CA2345985C (en) | Substituted 1,3-diaryl-2-pyrid-2-yl-3-(pyrid-2-ylamino)propanol derivatives,processes for their preparation, pharmaceuticals comprising these compounds and their use | |
| CN118725014A (zh) | 线粒体靶向肽 | |
| JPH07505877A (ja) | α−アミノボロン酸ペプチド及びエラスターゼ阻害剤としてのそれらの使用 | |
| CA2235586A1 (en) | Thrombin inhibitors | |
| CA2677487A1 (en) | Compounds and compositions as channel activating protease inhibitors | |
| TW403762B (en) | Novel peptidy1 elastase inhibitors substituted with nitrogen-containing heterocyclic groups and pharmaceutical compositions containing the same | |
| JPH07508748A (ja) | ヒト白血球エラスターゼに対する阻害剤としてのフッ素含有ジペプチド | |
| AU757366B2 (en) | Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism | |
| AU709088B2 (en) | Thrombin inhibitors | |
| JP2000514818A (ja) | ブラジキニン拮抗剤としてのｎ−ベンゼンスルホニル−ｌ−プロリン誘導体 | |
| JP2001504854A (ja) | 新規なｎ−ベンゼンスルホニル−ｌ−プロリン化合物、それらの製造方法及び治療法における使用 | |
| MXPA01003145A (en) | Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof | |
| JPH01230578A (ja) | プロリルエンドペプチダーゼ阻害剤 | |
| JPH01199962A (ja) | ピペリジン化合物 | |
| HK40116853A (en) | Mitochondria-targeting peptides | |
| HK40107199A (zh) | 线粒体靶向肽 | |
| JPH029863A (ja) | トリ置換−１，２，３，４−テトラヒドロイソキノリン | |
| JP3007613B2 (ja) | 成長ホルモン放出特性を有する化合物 | |
| AU684086B2 (en) | New peptide derivatives | |
| HK40039982B (en) | Mitochondria-targeting peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |